Memorial Sloan Kettering Cancer Center
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- Conditions
- RelapsedAcute LeukemiaNewly Diagnosed
- Interventions
- Other: assessments
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1365
- Registration Number
- NCT02677064
- Locations
- ๐บ๐ธ
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
๐บ๐ธLehigh Valley Health Network, Allentown, Pennsylvania, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
- Conditions
- Solid Tumor CancersBladder CancerLung CancerUrinary Tract Cancers
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 131
- Registration Number
- NCT02675829
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
๐บ๐ธMemorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT02673333
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธUniversity of Michigan (Data or Specimen Analysis Only), Ann Arbor, Michigan, United States
Pilot Trial of Homebound Stem Cell Transplantation
- Conditions
- Plasma Cell Dyscrasia
- Interventions
- Behavioral: Home monitoring teleconsult visitsBehavioral: Patient Reported Outcomes (PRO)Behavioral: Caregiver Reported Outcomes instruments
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 91
- Registration Number
- NCT02671448
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Prospective Registry of Multiplex Testing (PROMPT)
- Conditions
- Genetic Testing
- Interventions
- Other: saliva specimenBehavioral: questionnaire
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 689
- Registration Number
- NCT02665195
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธMemorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
- Conditions
- GliomaRecurrent Malignant Glioma
- Interventions
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT02658279
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Westchester, Harrison, New York, United States
๐บ๐ธMemorial Sloan Kettering Commack, Commack, New York, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
- Conditions
- Bladder CancerNon-Muscle-Invasive Urothelial Carcinoma
- Interventions
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02657486
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Single-agent Cobimetinib for Adults With Histiocytic Disorders
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT02649972
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
- Conditions
- Central Nervous System (CNS) MetastasesMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02650752
- Locations
- ๐บ๐ธ
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
- Conditions
- NeuroblastomaHigh-Risk
- Interventions
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 85
- Registration Number
- NCT02650648
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States